Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04EYG
|
|||
| Former ID |
DIB013762
|
|||
| Drug Name |
Ranibizumab
|
|||
| Synonyms |
Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hereditary hemorrhagic telangiectasia [ICD-11: LA90.00; ICD-10: I78, I78.0] | Approved | [1], [2] | |
| Company |
Genentech Inc
|
|||
| ADReCS Drug ID | BADD_D01912 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6779). | |||
| REF 2 | Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006 Sep;19(3):361-72. | |||
| REF 3 | Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.